11-Deoxycortisol may be superior to cortisol in confirming a successful adrenal vein catheterization without cosyntropin: a pilot study.

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2017-05-01 Epub Date: 2017-04-27 DOI:10.2217/ije-2016-0020

Naris Nilubol, Steven J Soldin, Dhaval Patel, Muthoni Rwenji, Jianghong Gu, Likhona S Masika, Richard Chang, Constantine A Stratakis, Electron Kebebew

{"title":"11-Deoxycortisol may be superior to cortisol in confirming a successful adrenal vein catheterization without cosyntropin: a pilot study.","authors":"Naris Nilubol, Steven J Soldin, Dhaval Patel, Muthoni Rwenji, Jianghong Gu, Likhona S Masika, Richard Chang, Constantine A Stratakis, Electron Kebebew","doi":"10.2217/ije-2016-0020","DOIUrl":null,"url":null,"abstract":"Aim: We aimed to compare the performance of nine adrenal steroids in confirming the correct catheter position during adrenal venous sampling (AVS) without cosyntropin in patients with primary hyperaldosteronism.Materials & methods: A successful adrenal vein catheterization without cosyntropin was defined as the ratio of steroids from adrenal to peripheral veins being >3:1. AVS samples from four patients with primary hyperaldosteronism were analyzed.Results: Compared with the mean ratio of cortisol without cosyntropin, the ratios of 11-deoxycortisol (p = 0.008), dehydroepiandrosterone (p = 0.01) and androstenedione (p = 0.008) were significantly higher. None of the ratios (n = 8) of cortisol from adrenal to peripheral veins exceeded 3:1, while all ratios of 11-deoxycortisol (p < 0.001) were >3.Conclusion: Cosyntropin infusion during AVS may not be necessary if 11-deoxycortisol is used to confirm catheter position.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ije-2016-0020","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrine Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ije-2016-0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/4/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

Abstract

Aim: We aimed to compare the performance of nine adrenal steroids in confirming the correct catheter position during adrenal venous sampling (AVS) without cosyntropin in patients with primary hyperaldosteronism.

Materials & methods: A successful adrenal vein catheterization without cosyntropin was defined as the ratio of steroids from adrenal to peripheral veins being >3:1. AVS samples from four patients with primary hyperaldosteronism were analyzed.

Results: Compared with the mean ratio of cortisol without cosyntropin, the ratios of 11-deoxycortisol (p = 0.008), dehydroepiandrosterone (p = 0.01) and androstenedione (p = 0.008) were significantly higher. None of the ratios (n = 8) of cortisol from adrenal to peripheral veins exceeded 3:1, while all ratios of 11-deoxycortisol (p < 0.001) were >3.

Conclusion: Cosyntropin infusion during AVS may not be necessary if 11-deoxycortisol is used to confirm catheter position.

Abstract Image

查看原文本刊更多论文

一项初步研究表明，去氧皮质醇可能优于皮质醇，可证实无共syntropin的肾上腺静脉导管置入术成功。

目的:比较原发性高醛固酮增多症患者在无共syntropin的情况下进行肾上腺静脉取样(AVS)时，九种肾上腺激素在确定正确导管位置方面的表现。材料与方法:肾上腺静脉置管成功的标准是肾上腺静脉与外周静脉的类固醇比例大于3:1。分析了4例原发性高醛固酮增多症患者的AVS样本。结果:与不含共syntropin的皮质醇的平均比值相比，11-脱氧皮质醇(p = 0.008)、脱氢表雄酮(p = 0.01)和雄烯二酮(p = 0.008)的比值显著升高。肾上腺皮质皮质醇与外周静脉的比值均未超过3:1 (n = 8)，而11-脱氧皮质醇的比值均>3 (p < 0.001)。结论:如果使用11-脱氧皮质醇来确定导管位置，AVS期间可能不需要注射共syntropin。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.